Details of the Drug Combination

General Information of Drug Combination (ID: DCVPMTF)

Drug Combination Name
Pralatrexate Levoleucovorin
Indication
Disease Entry Status REF
Non-Small Cell Lung Cancer Phase 1 [1]
Component Drugs Pralatrexate   DMAO80I Levoleucovorin   DMH5LME
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Pralatrexate
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [2]
Peripheral T-cell lymphoma 2A90.C Approved [2]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [3]
Pralatrexate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Polypeptide deformylase (PDF) TT9SL3Q DEFM_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Pralatrexate Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Folate transporter 1 (SLC19A1) DTOSN46 S19A1_HUMAN Substrate [7]
Proton-coupled folate transporter (SLC46A1) DTDJEMI PCFT_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Pralatrexate Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Folylpolyglutamate synthase (FPGS) DECWT2V FOLC_HUMAN Metabolism [8]
------------------------------------------------------------------------------------
Indication(s) of Levoleucovorin
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Approved [4]
Colon adenocarcinoma N.A. Approved [5]
Colorectal carcinoma N.A. Approved [5]
Non-small-cell lung cancer 2C25.Y Approved [5]
Pervasive developmental disorder 6A00-6A0Z Approved [5]
Pneumocystis pneumonia CA40.20 Approved [5]
Rectal adenocarcinoma 2B92 Approved [5]
Rectum mucinous adenocarcinoma N.A. Approved [5]
Colon cancer 2B90.Z Investigative [5]
Colon mucinous adenocarcinoma N.A. Investigative [5]
Gastric cancer 2B72 Investigative [5]
Megaloblastic anemia N.A. Investigative [5]
Methotrexate toxicity N.A. Investigative [5]

References

1 ClinicalTrials.gov (NCT01820091) Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6840).
3 Pralatrexate FDA Label
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Levoleucovorin FDA Label
6 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
7 Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012 Aug;15(4):183-210.
8 Pralatrexate : evaluation of clinical efficacy and toxicity in T-cell lymphoma. Expert Opin Pharmacother. 2013 Mar;14(4):515-23.